Campbell & Co Investment Adviser’s Cytek Biosciences CTKB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Buy	+39,333	New	+$168K	0.01%	987

Other funds holding CTKB

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Campbell & Co Investment Adviser's CTKB Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 39,333 shares worth $174K. The stake represents 0.01% of the portfolio and ranks #987 among its holdings.

27 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Campbell & Co Investment Adviser held 39,333 shares of Cytek Biosciences worth $174K as of Q2 2026.
Cytek Biosciences was a new Campbell & Co Investment Adviser position in Q2 2026.
Cytek Biosciences made up 0.01% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #987 holding.
27 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.